Sign In
Buy NVO
$47.64
+0.230 (+0.485%)
At Close: Jun 25, 2026
NEW YORK , Aug. 16, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Novo Nordisk A/S ("Novo Nordisk" or the "Company") (NYSE: NVO). Such investors are
Eli Lilly Vs. Novo Nordisk: Correction Overly Done - GLP-1 Market Leadership/ Robust Pipelines Ahead
09:00am, Saturday, 16'th Aug 2025
The ongoing compounding/ regulatory headwinds have triggered LLY's and NVO's painful corrections, worsened by the notable market rotation to AI boom. LLY's double beat FQ2'25 performance, raised FY202
11 Dividend Aristocrats With Excellent Upside Potential In The Next Year
07:00am, Saturday, 16'th Aug 2025
Dividend Growth Outperformance: For over 50 years, dividend growers have delivered market-beating returns with lower volatility. The BTI Example: British American Tobacco went from six years of stagna
Novo Nordisk's Wegovy gets accelerated US FDA approval for liver disease MASH
05:37pm, Friday, 15'th Aug 2025
Novo Nordisk said on Friday the U.S. Food and Drug Administration had granted accelerated approval for its weight-loss drug Wegovy to treat a serious liver condition known as metabolic dysfunction-ass
Novo Nordisk A/S: Wegovy® approved in the US for the treatment of MASH
05:23pm, Friday, 15'th Aug 2025
Bagsværd, Denmark, 15 August 2025 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved an additional indication for Wegovy® (semaglutide 2.4 mg) based on a s
Why Novo Nordisk Flew Almost 3% Higher on Friday
05:15pm, Friday, 15'th Aug 2025
An archrival's pricing move was seen as beneficial for Novo Nordisk (NVO 2.88%) on Friday. As investors disseminated news of a dramatic increase in the cost of a product competing with the company's s
NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit
04:45pm, Friday, 15'th Aug 2025
NEW YORK , Aug. 15, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Novo Nordisk A/
Novo Nordisk's Lead Fades, Eli Lilly Holds Course For Outsized Gains, Says Analyst
01:54pm, Friday, 15'th Aug 2025
On Thursday, Eli Lilly and Co. LLY said it will sharply increase the list price of its weight-loss and type 2 diabetes drug Mounjaro (tirzepatide) in the United Kingdom.
BENSALEM, Pa., Aug. 15, 2025 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded
Novo Nordisk Stock Could Benefit From Eli Lilly's Weight-Loss Price Hikes
12:25pm, Friday, 15'th Aug 2025
The pricing of weight-loss drugs like Lilly's Zepbound and Novo's Wegovy is a pressure point for investors.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Novo To Contact Him Directly To Discuss Their Options If you purchased or acquired se
Will New CEO's Leadership Propel Novo Nordisk's Next Growth Wave?
10:11am, Friday, 15'th Aug 2025
Maziar Mike Doustdar takes office as NVO's new CEO, bringing a proven global growth record to tackle rising obesity market competition.
September 30, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against NVO
09:15am, Friday, 15'th Aug 2025
NEW YORK , Aug. 15, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit. CLASS DEFINITION: The
My Favorite 10 Real-Money Blue-Chip Bargains To Buy In August
07:00am, Friday, 15'th Aug 2025
Yield, growth, and valuation are the core drivers of long-term returns. Safety and quality protect against catastrophic losses and dividend cuts. Dividend growth stocks have outperformed over 50 years
SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Novo Nordisk A/S (NYSE: NVO) sec
